Chromosomal damage and atherosclerosis. A protective effect from simvastatin.

Area of Science:

• Genetics and Molecular Biology
• Cardiovascular Medicine
• Nephrology

Background:

• Uremic patients exhibit higher sister chromatid exchange rates, indicating increased genomic damage.
• Statins possess pleiotropic effects beyond cholesterol reduction, potentially influencing genomic stability.
• Atherosclerosis is linked to elevated sister chromatid exchange rates, particularly in hemodialyzed patients.

Purpose of the Study:

• To evaluate the impact of escalating simvastatin doses on sister chromatid exchange rates in cultured lymphocytes.
• To determine simvastatin's influence on genomic damage in patients with end-stage renal disease and atherosclerosis.
• To explore potential anti-atherogenic mechanisms of statins related to DNA repair or damage mitigation.

Main Methods:

• Cultured peripheral lymphocytes from healthy volunteers, carotid atherosclerosis patients, and hemodialyzed patients.
• Assessed sister chromatid exchange rates and high-frequency cells in lymphocyte cultures.
• Exposed cultures to varying doses of simvastatin or a vehicle control.

Main Results:

• Hemodialyzed patients showed significantly higher sister chromatid exchange rates and high-frequency cells compared to controls.
• A positive correlation was observed between sister chromatid exchange rates, high-frequency cells, and atherosclerosis severity.
• Simvastatin treatment dose-dependently reduced sister chromatid exchange rates and high-frequency cells, especially in end-stage renal disease patients.

Conclusions:

• Simvastatin mitigated genomic damage in cultured lymphocytes from hemodialyzed patients.
• The findings suggest statins may have protective effects against atherosclerosis development, possibly by enhancing DNA repair or reducing damage.
• Further research is needed to elucidate the precise mechanism of simvastatin's effect on genomic damage in uremic patients.